European stocks post worst month since 2022 as Iran war drags on

Stock prices on the trading floor of the Euronext NV stock exchange in Paris, France, on Tuesday, Aug. 5, 2025.

Bloomberg | Bloomberg | Getty Images

LONDON — European stocks rose on Tuesday but rounded-off their worst monthly performance in six years, as uncertainty over the trajectory of the Iran war lingers.

The pan-European Stoxx 600 climbed 0.43%, after briefly dipping into negative territory after the opening bell. All major bourses and most regional sectors finished the day in the green.

Despite clawing back some ground on Tuesday, the Stoxx 600 closed out March with a monthly decline of 7.99%, marking its biggest monthly loss since mid-2022.

Inflation in the euro zone jumped to 2.5% in March, according to the latest preliminary figures from Eurostat on Tuesday. Euro zone inflation was up from 1.9% in February and jumped well above the European Central Bank's 2% target, driven by global energy price rises.

Stocks in the Asia-Pacific region also whipsawed in volatile trading overnight after a report said U.S. President Donald Trump was looking to avoid a prolonged conflict in the Middle East.

The Wall Street Journal reported on Monday evening that Trump told aides he was willing to end U.S. military hostilities against Iran even if the Strait of Hormuz remained largely closed.

Trump and his aides are understood to believe an operation directed at reopening the critical chokepoint could prolong the conflict beyond the initial timeline for the war of up to six weeks, the WSJ said.

Meanwhile, U.S. Secretary of State Marco Rubio told Al Jazeera in an interview published Monday that Washington's objectives in Iran would take "weeks, not months" to achieve.

"Those objectives are the destruction of their air force, which has been achieved; the destruction of their navy, which has largely been achieved; a significant reduction in the number of missile launchers that they have, which we're well on our way to achieving; and we are going to destroy the factories that make those missiles and those drones that they are using to attack their neighbors and the United States and our presence in the region," he said. "We will achieve those objectives. We are well on our way or ahead of schedule. We will achieve them in weeks, not months."

Oil prices ticked higher on Tuesday morning after dropping in overnight trading following the WSJ report.

It also came after Trump on Monday had threatened to expand attacks to Iran's civilian energy infrastructure, including water desalination plants, if Tehran failed to reopen the Strait of Hormuz.

Unilever nears deal with McCormick

In corporate news, consumer goods giant Unilever announced on Tuesday that it was in advanced talks with McCormick to merge its foods business with the U.S. spice maker. A deal could be concluded today, the firm said.

"If a transaction were to proceed, it is currently contemplated that it would involve ... an upfront cash component of approximately $15.7 billion and the majority of the consideration in McCormick equity," Unilever said. "Upon completion of the transaction, it is expected that Unilever and its shareholders would hold 65% of the combined company."

Shares of Unilever closed Tuesday down over 7%.

Meanwhile, Novo Nordisk launched a multi-month subscription program on Tuesday for its Wegovy obesity drug products. Novo said the move will ensure cash-paying patients see lower, "predictable" monthly prices.

Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name.

The price cut comes as the Danish drugmaker aims to retain market share from rival Eli Lily.

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market. Eli Lilly holds a 60% share, according to most estimates.

Novo shares finished the day down 0.1%.

— CNBC's Anniek Bao, Elsa Ohlen and Annika Kim Constantino contributed to this market report.